Decision to proceed with Phase 3 follows completion of End-of-Phase 2 meeting with the U.S. FDA VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage… Read More
MONTREAL, QC– The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced they have signed a memorandum of understanding (MOU) with Moderna Canada to support biomanufacturing training for… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that… Read More
MISSISSAUGA, ON & KIRKLAND, QC – In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone… Read More
The active IND allows initiation of US research with Filament’s botanical psilocybin drug candidate for the potential treatment of substance use disorders including OUD VANCOUVER, BC – Filament Health Corp. (OTCQB:FLHLF)… Read More
